Drug Database · Clinicians

Dutasteride

Brands (11) Dutarid, Armadart, Avodart…Show all

5-alpha Reductase Inhibitor (5-alpha Reductase Inhibitors) US FDA class
5-alpha reductase inhibitor; Testosterone-5-alpha reductase inhibitor; and others PH FDA category

Rx · Prescription drug14 PH products
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 6ebce680-5f82-f28e-da92-809928dc0f8f, version date October 26, 2026 (Dutasteride · AvKARE). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • Dutasteride capsules is a 5 alpha-reductase inhibitor indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate t
  • improve symptoms, reduce the risk of acute urinary retention, and reduce the risk of the need for BPH-related surgery.
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE Dutasteride capsules is a 5 alpha-reductase inhibitor indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to: (1.1) improve symptoms, reduce the risk of acute urinary retention, and reduce the risk of the need for BPH-related surgery. Dutasteride capsules in combination with the alpha adrenergic antagonist, tamsulosin, are indicated for the treatment of symptomatic BPH in men with an enlarged prostate.

(1.2) Limitations of Use: Dutasteride capsules are not approved for the prevention of prostate cancer. (1.3) 1.1 Monotherapy Dutasteride capsules are indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to: improve symptoms, reduce the risk of acute urinary retention (AUR), and reduce the risk of the need for BPH-related surgery. 1.2 Combination With Alpha Adrenergic Antagonist Dutasteride capsules in combination with the alpha adrenergic antagonist, tamsulosin, are indicated for the treatment of symptomatic BPH in men with an enlarged prostate. 1.3 Limitations of Use Dutasteride capsules are not approved for the prevention of prostate cancer.

Contraindications

4 CONTRAINDICATIONS Dutasteride, USP is contraindicated for use in: Pregnancy. In animal reproduction and developmental toxicity studies, dutasteride, USP inhibited development of male fetus external genitalia. Therefore, dutasteride, USP may cause fetal harm when administered to a pregnant woman. If dutasteride, USP is used during pregnancy or if the patient becomes pregnant while taking dutasteride, USP, the patient should be apprised of the potential hazard to the fetus [see Warnings and Precautions (5.4), Use in Specific Populations (8.1)].

Patients with previously demonstrated clinically significant hypersensitivity (e.g., serious skin reactions, angioedema) to dutasteride, USP or other 5 alpha-reductase inhibitors [see Adverse Reactions (6.2)]. Pregnancy and women of childbearing potential. (4, 5.4, 8.1) Pediatric patients. (4) Patients with previously demonstrated, clinically significant hypersensitivity (e.g., serious skin reactions, angioedema) to dutasteride, USP or other 5 alpha-reductase inhibitors.

(4)

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label
  • The capsules should be swallowed whole and not chewed or opened, as contact with the capsule contents may result in irritation of the oropharyngeal mucosa. Dutasteride capsules may be administered with or without food. Monotherapy: 0.5 mg once daily. (2.1)
  • Combination with tamsulosin: 0.5 mg once daily and tamsulosin 0.4 mg once daily. (2.2)
  • Dosing considerations: Swallow whole. May take with or without food. (2)
2.1 Monotherapy

2.1 Monotherapy The recommended dose of dutasteride, USP is 1 capsule (0.5 mg) taken once daily.

2.2 Combination With Alpha Adrenergic Antagonist

2.2 Combination With Alpha Adrenergic Antagonist The recommended dose of dutasteride, USP is 1 capsule (0.5 mg) taken once daily and tamsulosin 0.4 mg taken once daily.

Dosing: Altered kidney function

From the US FDA label · Renal impairment (use in specific populations, clinical pharmacology)

8.6 Renal Impairment No dose adjustment is necessary for dutasteride in patients with renal impairment [see Clinical Pharmacology (12.3)].

Renal Impairment: The effect of renal impairment on dutasteride pharmacokinetics has not been studied. However, less than 0.1% of a steady-state 0.5 mg dose of dutasteride is recovered in human urine, so no adjustment in dosage is anticipated for patients with renal impairment.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Hepatic impairment

8.7 Hepatic Impairment The effect of hepatic impairment on dutasteride pharmacokinetics has not been studied. Because dutasteride is extensively metabolized, exposure could be higher in hepatically impaired patients. However, in a clinical trial where 60 subjects received 5 mg (10 times the therapeutic dose) daily for 24 weeks, no additional adverse events were observed compared with those observed at the therapeutic dose of 0.5 mg [see Clinical Pharmacology (12.3)].

US FDA label

Dosage forms

Philippines

  • Softgel capsule: 500 mcg, 500 mg
  • Film-coated tablet: 500 mcg
  • Capsule: 500 mcg

Registered products in the Philippines

14 products registered with the Food and Drug Administration (FDA) Philippines list Dutasteride as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products14
Philippine FDA-registered products for Dutasteride
Package insert
ArmadartDutasteride
500 mcg Softgel CapsuleAlu/PVC-PVDC Blister Pack x 15's (Box of 15's and 30's)
Rx
Yuyu Pharma Inc.Korea
H & B Pharma International Inc
DRP-14216
Jul 31, 2028
AvodartDutasteride
500 mcg Softgel CapsuleAlu/PVC/PVDC Blister Pack x 10's (Box of 30's and Box of 60's)
Rx
Delpharm Poznan S.A.Poland
GlaxoSmithKline Philippines Inc.
DR-XY29399
Jul 29, 2028
DugenDutasteride
500 mcg Film-coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Sydler Remedies Pvt. LimitedIndia
Medethix, Inc.
DRP-8733
Dec 1, 2029
DutapanDutasteride
500 mcg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 10’s); Alu/Alu Blister Pack x 10’s (Box of 30’s)
Rx
Akums Drugs & Pharmaceuticals Ltd. (Plant I-Solid Oral Dosage Facility)India
PPAN TradingImporter: Ambica International CorporationTrader: Unosource Pharma Ltd.
DRP-6015-02
Feb 20, 2030
DutaprostDutasteride
500 mcg Softgel CapsulePVC/PVDC Push-through Foil Pack X 10's (Box of 30's)
Rx
Humanwell Puracap Pharmaceuticals (Wuhan) Co., Ltd.China
AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc.
DRP-15184
May 21, 2029
DutaridDutasteride
500 mcg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's and 30's)
Rx
Nucare Labs LLPIndia
ECE Pharmaceuticals, Inc.Importer: Biophil Medical Equipment and Supplies Trading
DRP-16023
Oct 18, 2029
DutaridDutasteride
500 mcg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 10’s); Alu/Alu Blister Pack x 10’s (Box of 30’s)
Rx
Akums Drugs & Pharmaceuticals Ltd. (Plant I-Solid Oral Dosage Facility)India
ECE Pharmaceuticals, Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd.
DRP-6015
Feb 20, 2030
Dutasia 0.5Dutasteride
500 mcg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Sydler Remedies Pvt. Ltd.India
Qualicare Pharma, Inc.Importer: Ambica International Corporation
DRP-5373
Jul 7, 2029
DutastoneDutasteride
500 mcg CapsuleAlu/PVC/PE/PVDC blister pack x 10's (Box of 100's)
Rx
Titan Laboratories Pvt. Ltd.India
Triple Tact Import & Export Corp.
DRP-8874
May 22, 2031
DutawellDutasteride
500 mcg Softgel CapsuleAlu/PVC-PVDC Blister Pack x 10's (Box of 30's)
Rx
Humanwell Puracap Pharmaceuticals (Wuhan) Co. Ltd.China
Sandoval Distributors, Inc.
DRP-14055
Jun 8, 2028
DUTAXIADutasteride
500 mg Softgel CapsulePVC/PVDC Push-through Foil Pack x 10’s (Box of 30’s)
Rx
Humanwell Puracap Pharmaceuticals (Wuhan) Co., Ltd.China
FSPC Pharmaceuticals Inc.Importer: AMB HK Enterprises Inc.
DRP-15184-01
May 21, 2029
DutrideDutasteride
500 mcg Softgel CapsuleAlu/Clear PVC Blister Pack x 10’s Box of 30’s
Rx
Sterile-Gene Life Sciences (P) Ltd.India
Scriptmed, Inc.Importer: Ambica International CorporationTrader: Swati Spentose Pvt. Ltd.
DRP-6733
Jul 1, 2031
NoneDutasteride
500 mcg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 10’s)
Rx
Akums Drugs & Pharmaceuticals Ltd. (Plant I-Solid Oral Dosage Facility)India
Ambicare Pharmaceuticals Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd.
DRP-6015-01
Feb 20, 2030
(no brand name)Dutasteride
500 mcg Softgel CapsuleAlu-PVC/PVDC Blister Foil x 10's (Box of 30's)
Rx
Cyndea Pharma S.L.Spain
Ritemed Phils., Inc.
DRP-12151
Jun 21, 2027

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS 0.5 mg, opaque, yellow, oblong soft gelatin capsules imprinted with “A 75”. 0.5 mg soft gelatin capsules (3)

Warnings/Precautions

Warnings and precautions (US label) US FDA label
  • Dutasteride reduces serum prostate-specific antigen (PSA) concentration by approximately 50%. However, any confirmed increase in PSA while on dutasteride may signal the presence of prostate cancer and should be evaluated, even if those values are still within the normal range for untreated men. (5.1)
  • Dutasteride may increase the risk of high-grade prostate cancer. (5.2, 6.1)
  • Prior to initiating treatment with dutasteride, consideration should be given to other urological conditions that may cause similar symptoms. (5.3)
  • Women who are pregnant or could become pregnant should not handle dutasteride capsules due to potential risk to a male fetus. (5.4, 8.1)
  • Patients should not donate blood until 6 months after their last dose of dutasteride. (5.5)
5.1 Effects on Prostate-Specific Antigen (PSA) and the Use of PSA

5.1 Effects on Prostate-Specific Antigen (PSA) and the Use of PSA in Prostate Cancer Detection In clinical trials, dutasteride reduced serum PSA concentration by approximately 50% within 3 to 6 months of treatment. This decrease was predictable over the entire range of PSA values in subjects with symptomatic BPH, although it may vary in individuals.

Dutasteride may also cause decreases in serum PSA in the presence of prostate cancer. To interpret serial PSAs in men taking dutasteride, a new PSA baseline should be established at least 3 months after starting treatment and PSA monitored periodically thereafter. Any confirmed increase from the lowest PSA value while on dutasteride may signal the presence of prostate cancer and should be evaluated, even if PSA levels are still within the normal range for men not taking a 5 alpha-reductase inhibitor.

Noncompliance with dutasteride may also affect PSA test results. To interpret an isolated PSA value in a man treated with dutasteride for 3 months or more, the PSA value should be doubled for comparison with normal values in untreated men. The free-to-total PSA ratio (percent free PSA) remains constant, even under the influence of dutasteride.

If clinicians elect to use percent free PSA as an aid in the detection of prostate cancer in men receiving dutasteride, no adjustment to its value appears necessary. Co-administration of dutasteride and tamsulosin resulted in similar changes to serum PSA as dutasteride monotherapy.

5.2 Increased Risk of High-Grade Prostate Cancer

5.2 Increased Risk of High-Grade Prostate Cancer In men aged 50 to 75 years with a prior negative biopsy for prostate cancer and a baseline PSA between 2.5 ng/mL and 10 ng/mL taking dutasteride in the 4-year Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial, there was an increased incidence of Gleason score 8-10 prostate cancer compared with men taking placebo (dutasteride 1% versus placebo 0.5%) [see Indications and Usage (1.3), Adverse Reactions (6.1)]. In a 7-year placebo-controlled clinical trial with another 5 alpha-reductase inhibitor (finasteride 5 mg, PROSCAR 1), similar results for Gleason score 8-10 prostate cancer were observed (finasteride 1.8% versus placebo 1.1%). 5 alpha-reductase inhibitors may increase the risk of development of high-grade prostate cancer.

Whether the effect of 5 alpha-reductase inhibitors to reduce prostate volume or trial related factors impacted the results of these trials has not been established.

5.3 Evaluation for Other Urological Diseases

5.3 Evaluation for Other Urological Diseases Prior to initiating treatment with dutasteride, consideration should be given to other urological conditions that may cause similar symptoms. In addition, BPH and prostate cancer may coexist.

5.4 Exposure of Women

5.4 Exposure of Women—Risk to Male Fetus Dutasteride capsules should not be handled by a woman who is pregnant or who could become pregnant. Dutasteride is absorbed through the skin and could result in unintended fetal exposure. If a woman who is pregnant or who could become pregnant comes in contact with leaking dutasteride capsules, the contact area should be washed immediately with soap and water [see Use in Specific Populations (8.1)].

5.5 Blood Donation

5.5 Blood Donation Men being treated with dutasteride should not donate blood until at least 6 months have passed following their last dose. The purpose of this deferred period is to prevent administration of dutasteride to a pregnant female transfusion recipient.

5.6 Effect on Semen Characteristics

5.6 Effect on Semen Characteristics The effects of dutasteride 0.5 mg/day on semen characteristics were evaluated in normal volunteers aged 18 to 52 (n = 27 dutasteride, n = 23 placebo) throughout 52 weeks of treatment and 24 weeks of post-treatment follow-up. At 52 weeks, the mean percent reductions from baseline in total sperm count, semen volume and sperm motility were 23%, 26% and 18%, respectively, in the dutasteride group when adjusted for changes from baseline in the placebo group.

Sperm concentration and sperm morphology were unaffected. After 24 weeks of follow-up, the mean percent change in total sperm count in the dutasteride group remained 23% lower than baseline. While mean values for all semen parameters at all time-points remained within the normal ranges and did not meet predefined criteria for a clinically significant change (30%), 2 subjects in the dutasteride group had decreases in sperm count of greater than 90% from baseline at 52 weeks, with partial recovery at the 24-week follow-up.

The clinical significance of dutasteride’s effect on semen characteristics for an individual patient’s fertility is not known.

Drug interactions

Drug interactions (US label) US FDA label

Use with caution in patients taking potent, chronic CYP3A4 enzyme inhibitors (e.g., ritonavir). (7)

7.1 Cytochrome P450 3

7.1 Cytochrome P450 3A Inhibitors Dutasteride is extensively metabolized in humans by the CYP3A4 and CYP3A5 isoenzymes. The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. Because of the potential for drug-drug interactions, use caution when prescribing dutasteride to patients taking potent, chronic CYP3A4 enzyme inhibitors (e.g., ritonavir) [see Clinical Pharmacology (12.3)].

7.2 Alpha Adrenergic Antagonists

7.2 Alpha Adrenergic Antagonists The administration of dutasteride in combination with tamsulosin or terazosin has no effect on the steady-state pharmacokinetics of either alpha adrenergic antagonist. The effect of administration of tamsulosin or terazosin on dutasteride pharmacokinetic parameters has not been evaluated.

7.3 Calcium Channel Antagonists

7.3 Calcium Channel Antagonists Co-administration of verapamil or diltiazem decreases dutasteride clearance and leads to increased exposure to dutasteride. The change in dutasteride exposure is not considered to be clinically significant. No dose adjustment is recommended [see Clinical Pharmacology (12.3)].

7.4 Cholestyramine

7.4 Cholestyramine Administration of a single 5 mg dose of dutasteride followed 1 hour later by 12 g of cholestyramine does not affect the relative bioavailability of dutasteride [see Clinical Pharmacology (12.3)].

7.5 Digoxin

7.5 Digoxin Dutasteride does not alter the steady-state pharmacokinetics of digoxin when administered concomitantly at a dose of 0.5 mg/day for 3 weeks [see Clinical Pharmacology (12.3)].

7.6 Warfarin

7.6 Warfarin Concomitant administration of dutasteride 0.5 mg/day for 3 weeks with warfarin does not alter the steady-state pharmacokinetics of the S- or R-warfarin isomers or alter the effect of warfarin on prothrombin time [see Clinical Pharmacology (12.3)].

Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label

In vitro studies showed that dutasteride is metabolized by the CYP3A4 and CYP3A5 isoenzymes.

In addition, the 15-hydroxydutasteride metabolite was formed by CYP3A4.

Dutasteride is not metabolized in vitro by human cytochrome P450 isoenzymes CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 and CYP2E1.

Drug Interactions: Cytochrome P450 Inhibitors: No clinical drug interaction trials have been performed to evaluate the impact of CYP3A enzyme inhibitors on dutasteride pharmacokinetics.

However, based on in vitro data, blood concentrations of dutasteride may increase in the presence of inhibitors of CYP3A4/5 such as ritonavir, ketoconazole, verapamil, diltiazem, cimetidine, troleandomycin and ciprofloxacin.

Dutasteride does not inhibit the in vitro metabolism of model substrates for the major human cytochrome P450 isoenzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4) at a concentration of 1,000 ng/mL, 25 times greater than steady-state serum concentrations in humans.

Calcium Channel Antagonists: In a population pharmacokinetics analysis, a decrease in clearance of dutasteride was noted when co-administered with the CYP3A4 inhibitors verapamil (-37%, n = 6) and diltiazem (-44%, n = 5).

In contrast, no decrease in clearance was seen when amlodipine, another calcium channel antagonist that is not a CYP3A4 inhibitor, was co-administered with dutasteride (+7%, n = 4).

Adverse reactions

Adverse reactions (US label) US FDA label
  • The most common adverse reactions, reported in ≥1% of subjects treated with dutasteride and more commonly than in subjects treated with placebo, are impotence, decreased libido, ejaculation disorders and breast disorders. (6.1)
  • To report SUSPECTED ADVERSE REACTIONS, contact AvKARE at 1-855-361-3993 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience

6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trial of another drug and may not reflect the rates observed in practice. From clinical trials with dutasteride as monotherapy or in combination with tamsulosin: The most common adverse reactions reported in subjects receiving dutasteride were impotence, decreased libido, breast disorders (including breast enlargement and tenderness) and ejaculation disorders.

The most common adverse reactions reported in subjects receiving combination therapy (dutasteride plus tamsulosin) were impotence, decreased libido, breast disorders (including breast enlargement and tenderness), ejaculation disorders and dizziness. Ejaculation disorders occurred significantly more in subjects receiving combination therapy (11%) compared with those receiving dutasteride (2%) or tamsulosin (4%) as monotherapy.

Trial withdrawal due to adverse reactions occurred in 4% of subjects receiving dutasteride and 3% of subjects receiving placebo in placebo-controlled trials with dutasteride. The most common adverse reaction leading to trial withdrawal was impotence (1%). In the clinical trial evaluating the combination therapy, trial withdrawal due to adverse reactions occurred in 6% of subjects receiving combination therapy (dutasteride plus tamsulosin) and 4% of subjects receiving dutasteride or tamsulosin as monotherapy.

The most common adverse reaction in all treatment arms leading to trial withdrawal was erectile dysfunction (1% to 1.5%). Monotherapy: Over 4,300 male subjects with BPH were randomly assigned to receive placebo or 0.5 mg daily doses of dutasteride in three identical 2-year, placebo-controlled, double-blind, Phase 3 treatment trials, each followed by a 2-year open-label extension.

During the double-blind treatment period, 2,167 male subjects were exposed to dutasteride, including 1,772 exposed for 1 year and 1,510 exposed for 2 years. When including the open-label extensions, 1,009 male subjects were exposed to dutasteride for 3 years and 812 were exposed for 4 years. The population was aged 47 to 94 years (mean age: 66 years) and greater than 90% were Caucasian.

Table 1 summarizes clinical adverse reactions reported in at least 1% of subjects receiving dutasteride and at a higher incidence than subjects receiving placebo. Table 1. Adverse Reactions Reported in ≥1% of Subjects Over a 24-Month Period and More Frequently in the Group Receiving Dutasteride Than the Placebo Group (Randomized, Double-Blind, Placebo-Controlled Trials Pooled) by Time of Onset Adverse Reactions Adverse Reaction Time of Onset Months 0 to 6 Months 7 to 12 Months 13 to 18 Months 19 to 24 Dutasteride (n) (n = 2,167) (n = 1,901) (n = 1,725) (n = 1,605) Placebo (n) (n = 2,158) (n = 1,922) (n = 1,714) (n = 1,555) Impotence a Dutasteride 4.7% 1.4% 1% 0.8% Placebo 1.7% 1.5% 0.5% 0.9% Decreased libido a Dutasteride 3% 0.7% 0.3% 0.3% Placebo 1.4% 0.6% 0.2% 0.1% Ejaculation disorders a Dutasteride 1.4% 0.5% 0.5% 0.1% Placebo 0.5% 0.3% 0.1% 0% Breast disorders b Dutasteride 0.5% 0.8% 1.1% 0.6% Placebo 0.2% 0.3% 0.3% 0.1% a These sexual adverse reactions are associated with dutasteride treatment (including monotherapy and combination with tamsulosin).

These adverse reactions may persist after treatment discontinuation. The role of dutasteride in this persistence is unknown. b Includes breast tenderness and breast enlargement. Long-Term Treatment (Up to 4 Years): High-Grade Prostate Cancer: The REDUCE trial was a randomized, double-blind, placebo-controlled trial that enrolled 8,231 men aged 50 to 75 years with a serum PSA of 2.5 ng/mL to 10 ng/mL and a negative prostate biopsy within the previous 6 months.

Subjects were randomized to receive placebo (N = 4,126) or 0.5 mg daily doses of dutasteride (N = 4,105) for up to 4 years. The mean age was 63 years and 91% were Caucasian. Subjects underwent protocol-mandated scheduled prostate biopsies at 2 and 4 years of treatment or had “for-cause biopsies” at non-scheduled times if clinically indicated.

There was a higher incidence of Gleason score 8-10 prostate cancer in men receiving dutasteride (1%) compared with men on placebo (0.5%) [see Indications and Usage (1.3), Warnings and Precautions (5.2)]. In a 7-year placebo-controlled clinical trial with another 5 alpha-reductase inhibitor (finasteride 5 mg, PROSCAR 1), similar results for Gleason score 8-10 prostate cancer were observed (finasteride 1.8% versus placebo 1.1%).

No clinical benefit has been demonstrated in patients with prostate cancer treated with dutasteride. Reproductive and Breast Disorders: In the 3 pivotal placebo-controlled BPH trials with dutasteride, each 4 years in duration, there was no evidence of increased sexual adverse reactions (impotence, decreased libido and ejaculation disorder) or breast disorders with increased duration of treatment.

Among these 3 trials, there was 1 case of breast cancer in the dutasteride group and 1 case in the placebo group. No cases of breast cancer were reported in any treatment group in the 4-year CombAT trial or the 4-year REDUCE trial. The relationship between long-term use of dutasteride and male breast neoplasia is currently unknown.

Combination With Alpha-Blocker Therapy (CombAT): Over 4,800 male subjects with BPH were randomly assigned to receive 0.5 mg dutasteride, 0.4 mg tamsulosin, or combination therapy (0.5 mg dutasteride plus 0.4 mg tamsulosin) administered once daily in a 4-year double-blind trial. Overall, 1,623 subjects received monotherapy with dutasteride; 1,611 subjects received monotherapy with tamsulosin; and 1,610 subjects received combination therapy.

The population was aged 49 to 88 years (mean age: 66 years) and 88% were Caucasian. Table 2 summarizes adverse reactions reported in at least 1% of subjects in the combination group and at a higher incidence than subjects receiving monotherapy with dutasteride or tamsulosin. Table 2. Adverse Reactions Reported Over a 48-Month Period in ≥1% of Subjects and More Frequently in the Co-administration Therapy Group Than the Groups Receiving Monotherapy With Dutasteride or Tamsulosin (CombAT) by Time of Onset Adverse Reaction Adverse Reaction Time of Onset Year 1 Year 2 Year 3 Year 4 Months 0 to 6 Months 7 to 12 Combination a (n = 1,610) (n = 1,527) (n = 1,428) (n = 1,283) (n = 1,200) Dutasteride (n = 1,623) (n = 1,548) (n = 1,464) (n = 1,325) (n = 1,200) Tamsulosin (n = 1,611) (n = 1,545) (n = 1,468) (n = 1,281) (n = 1,112) Ejaculation disorders b,c Combination 7.8% 1.6% 1% 0.5% <0.1% Dutasteride 1% 0.5% 0.5% 0.2% 0.3% Tamsulosin 2.2% 0.5% 0.5% 0.2% 0.3% Impotence c,d Combination 5.4% 1.1% 1.8% 0.9% 0.4% Dutasteride 4% 1.1% 1.6% 0.6% 0.3% Tamsulosin 2.6% 0.8% 1% 0.6% 1.1% Decreased libido c,e Combination 4.5% 0.9% 0.8% 0.2% 0% Dutasteride 3.1% 0.7% 1.0% 0.2% 0% Tamsulosin 2.0% 0.6% 0.7% 0.2% <0.1% Breast disorders f Combination 1.1% 1.1% 0.8% 0.9% 0.6% Dutasteride 0.9% 0.9% 1.2% 0.5% 0.7% Tamsulosin 0.4% 0.4% 0.4% 0.2% 0% Dizziness Combination 1.1% 0.4% 0.1% <0.1% 0.2% Dutasteride 0.5% 0.3% 0.1% <0.1% <0.1% Tamsulosin 0.9% 0.5% 0.4% <0.1% 0% a Combination = Dutasteride 0.5 mg once daily plus tamsulosin 0.4 mg once daily. b Includes anorgasmia, retrograde ejaculation, semen volume decreased, orgasmic sensation decreased, orgasm abnormal, ejaculation delayed, ejaculation disorder, ejaculation failure and premature ejaculation. c These sexual adverse reactions are associated with dutasteride treatment (including monotherapy and combination with tamsulosin).

These adverse reactions may persist after treatment discontinuation. The role of dutasteride in this persistence is unknown. d Includes erectile dysfunction and disturbance in sexual arousal. e Includes libido decreased, libido disorder, loss of libido, sexual dysfunction, and male sexual dysfunction. f Includes breast enlargement, gynecomastia, breast swelling, breast pain, breast tenderness, nipple pain and nipple swelling.

Cardiac Failure: In CombAT, after 4 years of treatment, the incidence of the composite term cardiac failure in the combination therapy group (12/1,610; 0.7%) was higher than in either monotherapy group: dutasteride, 2/1,623 (0.1%) and tamsulosin, 9/1,611 (0.6%). Composite cardiac failure was also examined in a separate 4-year placebo-controlled trial evaluating dutasteride in men at risk for development of prostate cancer.

The incidence of cardiac failure in subjects taking dutasteride was 0.6% (26/4,105) compared with 0.4% (15/4,126) in subjects on placebo. A majority of subjects with cardiac failure in both trials had comorbidities associated with an increased risk of cardiac failure. Therefore, the clinical significance of the numerical imbalances in cardiac failure is unknown.

No causal relationship between dutasteride alone or in combination with tamsulosin and cardiac failure has been established. No imbalance was observed in the incidence of overall cardiovascular adverse events in either trial.

6.2 Postmarketing Experience

6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of dutasteride. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

These reactions have been chosen for inclusion due to a combination of their seriousness, frequency of reporting, or potential causal connection to dutasteride. Immune System Disorders: Hypersensitivity reactions, including rash, pruritus, urticaria, localized edema, serious skin reactions and angioedema. Neoplasms: Male breast cancer.

Psychiatric Disorders: Depressed mood. Reproductive System and Breast Disorders: Testicular pain and testicular swelling. To report SUSPECTED ADVERSE REACTIONS contact AvKARE at 1-855-361-3993; email [email protected]; or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Adverse reaction frequency tables (US label) US FDA label
Table 1. Adverse Reactions Reported in ≥1% of Subjects Over a 24-Month Period and More Frequently in the Group Receiving Dutasteride Than the Placebo Group (Randomized, Double-Blind, Placebo-Controlled Trials Pooled) by Time of Onset
Adverse Reactions Adverse Reaction Time of Onset
Months 0 to 6 Months 7 to 12 Months 13 to 18 Months 19 to 24
Dutasteride (n) (n = 2,167) (n = 1,901) (n = 1,725) (n = 1,605)
Placebo (n) (n = 2,158) (n = 1,922) (n = 1,714) (n = 1,555)
Impotence a
Dutasteride 4.7% 1.4% 1% 0.8%
Placebo 1.7% 1.5% 0.5% 0.9%
Decreased libido a
Dutasteride 3% 0.7% 0.3% 0.3%
Placebo 1.4% 0.6% 0.2% 0.1%
Ejaculation disorders a
Dutasteride 1.4% 0.5% 0.5% 0.1%
Placebo 0.5% 0.3% 0.1% 0%
Breast disorders b
Dutasteride 0.5% 0.8% 1.1% 0.6%
Placebo 0.2% 0.3% 0.3% 0.1%
a These sexual adverse reactions are associated with dutasteride treatment (including monotherapy and combination with tamsulosin). These adverse reactions may persist after treatment discontinuation. The role of dutasteride in this persistence is unknown.
b Includes breast tenderness and breast enlargement.
Table 2. Adverse Reactions Reported Over a 48-Month Period in ≥1% of Subjects and More Frequently in the Co-administration Therapy Group Than the Groups Receiving Monotherapy With Dutasteride or Tamsulosin (CombAT) by Time of Onset
Adverse Reaction Adverse Reaction Time of Onset
Year 1 Year 2 Year 3 Year 4
Months 0 to 6 Months 7 to 12
Combination a (n = 1,610) (n = 1,527) (n = 1,428) (n = 1,283) (n = 1,200)
Dutasteride (n = 1,623) (n = 1,548) (n = 1,464) (n = 1,325) (n = 1,200)
Tamsulosin (n = 1,611) (n = 1,545) (n = 1,468) (n = 1,281) (n = 1,112)
Ejaculation disorders b,c
Combination 7.8% 1.6% 1% 0.5% <0.1%
Dutasteride 1% 0.5% 0.5% 0.2% 0.3%
Tamsulosin 2.2% 0.5% 0.5% 0.2% 0.3%
Impotence c,d
Combination 5.4% 1.1% 1.8% 0.9% 0.4%
Dutasteride 4% 1.1% 1.6% 0.6% 0.3%
Tamsulosin 2.6% 0.8% 1% 0.6% 1.1%
Decreased libido c,e
Combination 4.5% 0.9% 0.8% 0.2% 0%
Dutasteride 3.1% 0.7% 1.0% 0.2% 0%
Tamsulosin 2.0% 0.6% 0.7% 0.2% <0.1%
Breast disorders f
Combination 1.1% 1.1% 0.8% 0.9% 0.6%
Dutasteride 0.9% 0.9% 1.2% 0.5% 0.7%
Tamsulosin 0.4% 0.4% 0.4% 0.2% 0%
Dizziness
Combination 1.1% 0.4% 0.1% <0.1% 0.2%
Dutasteride 0.5% 0.3% 0.1% <0.1% <0.1%
Tamsulosin 0.9% 0.5% 0.4% <0.1% 0%
a Combination = Dutasteride 0.5 mg once daily plus tamsulosin 0.4 mg once daily.
b Includes anorgasmia, retrograde ejaculation, semen volume decreased, orgasmic sensation decreased, orgasm abnormal, ejaculation delayed, ejaculation disorder, ejaculation failure and premature ejaculation.
cThese sexual adverse reactions are associated with dutasteride treatment (including monotherapy and combination with tamsulosin). These adverse reactions may persist after treatment discontinuation. The role of dutasteride in this persistence is unknown.
d Includes erectile dysfunction and disturbance in sexual arousal.
e Includes libido decreased, libido disorder, loss of libido, sexual dysfunction, and male sexual dysfunction.
f Includes breast enlargement, gynecomastia, breast swelling, breast pain, breast tenderness, nipple pain and nipple swelling.

Pharmacokinetics

Half-life and elimination (verbatim, US label)

Dutasteride and its metabolites were excreted mainly in feces.

The terminal elimination half-life of dutasteride is approximately 5 weeks at steady-state.

Due to the long half-life of dutasteride, serum concentrations remain detectable (greater than 0.1 ng/mL) for up to 4 to 6 months after discontinuation of treatment.

In this single-dose trial, dutasteride half-life increased with age (approximately 170 hours in men aged 20 to 49 years, approximately 260 hours in men aged 50 to 69 years, and approximately 300 hours in men older than 70 years).

Pharmacokinetics (US label) US FDA label

12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Dutasteride inhibits the conversion of testosterone to dihydrotestosterone (DHT). DHT is the androgen primarily responsible for the initial development and subsequent enlargement of the prostate gland. Testosterone is converted to DHT by the enzyme 5 alpha-reductase, which exists as 2 isoforms, type 1 and type 2.

The type 2 isoenzyme is primarily active in the reproductive tissues, while the type 1 isoenzyme is also responsible for testosterone conversion in the skin and liver. Dutasteride is a competitive and specific inhibitor of both type 1 and type 2 5 alpha-reductase isoenzymes, with which it forms a stable enzyme complex. Dissociation from this complex has been evaluated under in vitro and in vivo conditions and is extremely slow.

Dutasteride does not bind to the human androgen receptor. 12.2 Pharmacodynamics Effect on 5 Alpha-Dihydrotestosterone and Testosterone: The maximum effect of daily doses of dutasteride on the reduction of DHT is dose dependent and is observed within 1 to 2 weeks. After 1 and 2 weeks of daily dosing with dutasteride 0.5 mg, median serum DHT concentrations were reduced by 85% and 90%, respectively.

In patients with BPH treated with dutasteride 0.5 mg/day for 4 years, the median decrease in serum DHT was 94% at 1 year, 93% at 2 years and 95% at both 3 and 4 years. The median increase in serum testosterone was 19% at both 1 and 2 years, 26% at 3 years and 22% at 4 years, but the mean and median levels remained within the physiologic range.

In patients with BPH treated with 5 mg/day of dutasteride or placebo for up to 12 weeks prior to transurethral resection of the prostate, mean DHT concentrations in prostatic tissue were significantly lower in the dutasteride group compared with placebo (784 and 5,793 pg/g, respectively, P <0.001). Mean prostatic tissue concentrations of testosterone were significantly higher in the dutasteride group compared with placebo (2,073 and 93 pg/g, respectively, P <0.001).

Adult males with genetically inherited type 2 5 alpha-reductase deficiency also have decreased DHT levels. These 5 alpha-reductase-deficient males have a small prostate gland throughout life and do not develop BPH. Except for the associated urogenital defects present at birth, no other clinical abnormalities related to 5 alpha-reductase deficiency have been observed in these individuals.

Effects on Other Hormones: In healthy volunteers, 52 weeks of treatment with dutasteride 0.5 mg/day (n = 26) resulted in no clinically significant change compared with placebo (n = 23) in sex hormone-binding globulin, estradiol, luteinizing hormone, follicle-stimulating hormone, thyroxine (free T4) and dehydroepiandrosterone. Statistically significant, baseline-adjusted mean increases compared with placebo were observed for total testosterone at 8 weeks (97.1 ng/dL, P <0.003) and thyroid-stimulating hormone at 52 weeks (0.4 mcIU/mL, P <0.05).

The median percentage changes from baseline within the dutasteride group were 17.9% for testosterone at 8 weeks and 12.4% for thyroid-stimulating hormone at 52 weeks. After stopping dutasteride for 24 weeks, the mean levels of testosterone and thyroid-stimulating hormone had returned to baseline in the group of subjects with available data at the visit.

In subjects with BPH treated with dutasteride in a large randomized, double-blind, placebo-controlled trial, there was a median percent increase in luteinizing hormone of 12% at 6 months and 19% at both 12 and 24 months. Other Effects: Plasma lipid panel and bone mineral density were evaluated following 52 weeks of dutasteride 0.5 mg once daily in healthy volunteers.

There was no change in bone mineral density as measured by dual energy x-ray absorptiometry compared with either placebo or baseline. In addition, the plasma lipid profile (i.e., total cholesterol, low density lipoproteins, high density lipoproteins and triglycerides) was unaffected by dutasteride. No clinically significant changes in adrenal hormone responses to adrenocorticotropic hormone (ACTH) stimulation were observed in a subset population (n = 13) of the 1-year healthy volunteer trial. 12.3 Pharmacokinetics Absorption: Following administration of a single 0.5 mg dose of a soft gelatin capsule, time to peak serum concentrations (T max) of dutasteride occurs within 2 to 3 hours.

Absolute bioavailability in 5 healthy subjects is approximately 60% (range: 40% to 94%). When the drug is administered with food, the maximum serum concentrations were reduced by 10% to 15%. This reduction is of no clinical significance. Distribution: Pharmacokinetic data following single and repeat oral doses show that dutasteride has a large volume of distribution (300 to 500 L).

Dutasteride is highly bound to plasma albumin (99%) and alpha-1 acid glycoprotein (96.6%). In a trial of healthy subjects (n = 26) receiving dutasteride 0.5 mg/day for 12 months, semen dutasteride concentrations averaged 3.4 ng/mL (range, 0.4 to 14 ng/mL) at 12 months and, similar to serum, achieved steady-state concentrations at 6 months.

On average, at 12 months 11.5% of serum dutasteride concentrations partitioned into semen. Metabolism and Elimination: Dutasteride is extensively metabolized in humans. In vitro studies showed that dutasteride is metabolized by the CYP3A4 and CYP3A5 isoenzymes. Both of these isoenzymes produced the 4′-hydroxydutasteride, 6-hydroxydutasteride and the 6,4′-dihydroxydutasteride metabolites.

In addition, the 15-hydroxydutasteride metabolite was formed by CYP3A4. Dutasteride is not metabolized in vitro by human cytochrome P450 isoenzymes CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 and CYP2E1. In human serum following dosing to steady state, unchanged dutasteride, 3 major metabolites (4′-hydroxydutasteride, 1,2-dihydrodutasteride and 6-hydroxydutasteride) and 2 minor metabolites (6,4′-dihydroxydutasteride and 15-hydroxydutasteride), as assessed by mass spectrometric response, have been detected.

The absolute stereochemistry of the hydroxyl additions in the 6 and 15 positions is not known. In vitro, the 4′-hydroxydutasteride and 1,2-dihydrodutasteride metabolites are much less potent than dutasteride against both isoforms of human 5 alpha-reductase. The activity of 6β-hydroxydutasteride is comparable to that of dutasteride.

Dutasteride and its metabolites were excreted mainly in feces. As a percent of dose, there was approximately 5% unchanged dutasteride (~1% to ~15%) and 40% as dutasteride-related metabolites (~2% to ~90%). Only trace amounts of unchanged dutasteride were found in urine (<1%). Therefore, on average, the dose unaccounted for approximated 55% (range: 5% to 97%).

The terminal elimination half-life of dutasteride is approximately 5 weeks at steady-state. The average steady-state serum dutasteride concentration was 40 ng/mL following 0.5 mg/day for 1 year. Following daily dosing, dutasteride serum concentrations achieve 65% of steady-state concentration after 1 month and approximately 90% after 3 months.

Due to the long half-life of dutasteride, serum concentrations remain detectable (greater than 0.1 ng/mL) for up to 4 to 6 months after discontinuation of treatment. Specific Populations: Pediatric: Dutasteride pharmacokinetics have not been investigated in subjects younger than 18 years. Geriatric: No dose adjustment is necessary in the elderly.

The pharmacokinetics and pharmacodynamics of dutasteride were evaluated in 36 healthy male subjects aged between 24 and 87 years following administration of a single 5 mg dose of dutasteride. In this single-dose trial, dutasteride half-life increased with age (approximately 170 hours in men aged 20 to 49 years, approximately 260 hours in men aged 50 to 69 years, and approximately 300 hours in men older than 70 years).

Of 2,167 men treated with dutasteride in the 3 pivotal trials, 60% were age 65 and over and 15% were age 75 and over. No overall differences in safety or efficacy were observed between these patients and younger patients. Gender: Dutasteride is contraindicated in pregnancy and women of childbearing potential and is not indicated for use in other women [see Contraindications (4), Warnings and Precautions (5.1)].

The pharmacokinetics of dutasteride in women have not been studied. Race: The effect of race on dutasteride pharmacokinetics has not been studied. Renal Impairment: The effect of renal impairment on dutasteride pharmacokinetics has not been studied. However, less than 0.1% of a steady-state 0.5 mg dose of dutasteride is recovered in human urine, so no adjustment in dosage is anticipated for patients with renal impairment.

Hepatic Impairment: The effect of hepatic impairment on dutasteride pharmacokinetics has not been studied. Because dutasteride is extensively metabolized, exposure could be higher in hepatically impaired patients. Drug Interactions: Cytochrome P450 Inhibitors: No clinical drug interaction trials have been performed to evaluate the impact of CYP3A enzyme inhibitors on dutasteride pharmacokinetics.

However, based on in vitro data, blood concentrations of dutasteride may increase in the presence of inhibitors of CYP3A4/5 such as ritonavir, ketoconazole, verapamil, diltiazem, cimetidine, troleandomycin and ciprofloxacin. Dutasteride does not inhibit the in vitro metabolism of model substrates for the major human cytochrome P450 isoenzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4) at a concentration of 1,000 ng/mL, 25 times greater than steady-state serum concentrations in humans.

Alpha Adrenergic Antagonists: In a single-sequence, crossover study in healthy volunteers, the administration of tamsulosin or terazosin in combination with dutasteride had no effect on the steady-state pharmacokinetics of either alpha adrenergic antagonist. Although the effect of administration of tamsulosin or terazosin on dutasteride pharmacokinetic parameters was not evaluated, the percent change in DHT concentrations was similar for dutasteride alone compared with the combination treatment.

Calcium Channel Antagonists: In a population pharmacokinetics analysis, a decrease in clearance of dutasteride was noted when co-administered with the CYP3A4 inhibitors verapamil (-37%, n = 6) and diltiazem (-44%, n = 5). In contrast, no decrease in clearance was seen when amlodipine, another calcium channel antagonist that is not a CYP3A4 inhibitor, was co-administered with dutasteride (+7%, n = 4).

The decrease in clearance and subsequent increase in exposure to dutasteride in the presence of verapamil and diltiazem is not considered to be clinically significant. No dose adjustment is recommended. Cholestyramine: Administration of a single 5 mg dose of dutasteride followed 1 hour later by 12 g cholestyramine did not affect the relative bioavailability of dutasteride in 12 normal volunteers.

Digoxin: In a trial of 20 healthy volunteers, dutasteride did not alter the steady-state pharmacokinetics of digoxin when administered concomitantly at a dose of 0.5 mg/day for 3 weeks. Warfarin: In a trial of 23 healthy volunteers, 3 weeks of treatment with dutasteride 0.5 mg/day did not alter the steady-state pharmacokinetics of the S- or R-warfarin isomers or alter the effect of warfarin on prothrombin time when administered with warfarin.

Other Concomitant Therapy: Although specific interaction trials were not performed with other compounds, approximately 90% of the subjects in the 3 randomized, double-blind, placebo-controlled safety and efficacy trials receiving dutasteride were taking other medications concomitantly. No clinically significant adverse interactions could be attributed to the combination of dutasteride and concurrent therapy when dutasteride was co-administered with anti-hyperlipidemics, angiotensin-converting enzyme (ACE) inhibitors, beta-adrenergic blocking agents, calcium channel blockers, corticosteroids, diuretics, nonsteroidal anti-inflammatory drugs (NSAIDs), phosphodiesterase Type V inhibitors and quinolone antibiotics.

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Dutasteride · AvKARE [US FDA-approved label, version 6, October 26, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6ebce680-5f82-f28e-da92-809928dc0f8f
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .